Brief: Vivoryon Therapeutics 9-Month Net Loss Widens To 18.9 Million Eurs

Vivoryon Therapeutics NV

22/11/2022 06:37

Nov 22 (Reuters) - Vivoryon Therapeutics NV  05Y.F :
    * THIRD QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS
OPERATIONAL
PROGRESS
    * CASH FLOWS PROVIDED FROM FINANCING ACTIVITIES WERE EUR
19.1
MILLION FOR THE NINE MONTHS ENDED  SEPTEMBER 30, 2022
    * NET LOSS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 WAS
EUR
18.9 MILLION, COMPARED TO EUR 7.3 MILLION FOR THE NINE MONTHS
ENDED SEPTEMBER 30, 2021resf
    * EXPECTS THAT ITS EXISTING CASH AND CASH  EQUIVALENTS WILL
BE
SUFFICIENT TO FUND ITS RESEARCH AND DEVELOPMENT EXPENSES
    * IN NINE MONTHS ENDED SEPTEMBER 30, 2021, THE COMPANY
GENERATED
LICENSE REVENUES OF EUR 10.8 MILLION FROM A STRATEGIC REGIONAL
LICENSING PARTNERSHIP IN CHINA
    * RESEARCH AND DEVELOPMENT EXPENSES INCREASED BY EUR 2.5
MILLION
TO EUR 16.1 MILLION IN THE  NINE MONTHS ENDED SEPTEMBER 30, 2022

Source text: https://bit.ly/3V4AjyQ
Further company coverage:  05Y.F 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))